ClinicalTrials.gg
Active, not recruitingNCT07466017Updated Aug 10, 2026

A Study of CS060380 Tablets in Patients With MASH and Obesity

A Phase 2 interventional study of semaglutide and CS060380 in Metabolic Dysfunction-associated Steatohepatitis (MASH) and Obesity, sponsored by Cascade Pharmaceuticals, Inc. Active, not recruiting at 12 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Cascade Pharmaceuticals, Inc · Phase 2, Interventional, and Treatment

How we know · 6 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 603 studies in Obesity with a site in China — 223 open to participants now, 284 under way, 67 of them phase 3. Obesity · China.

Enrollment
228th of 504
130 · median 120
Started
2026
with 135 others
Phase 2
52 of 603
17 open now
Primary completion
2027-04
later than 157 of 282 live
Registered
468th of 603
by date

Among the 603 studies in Obesity with a site in China, this one is the 228th largest by enrollment of the 504 interventional ones that give a count, is one of 136 that started in 2026, is one of 52 in phase 2, reaches primary completion later than 157 of the 282 other live ones, and was the 468th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

223 of the 603 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

218 more — sign in →

All 223 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 603 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

this study is looking at a new investigational medicine called CS060380, when used together with semaglutide, in adults who have both metabolic dysfunction-associated steatohepatitis (MASH) and obesity. MASH is a condition where too much fat builds up in the liver, leading to inflammation and damage. Obesity is a major risk factor for this condition.

This is a Phase II clinical trial, which means we are testing the medicine to see if it works and is safe. The study will last up to 54 weeks, which is a little over a year. It includes:

  • A screening period of up to 2 weeks to check if you are eligible to take part.
  • A 36-week double-blind treatment period, where you will be randomly assigned (like flipping a coin) to receive either the study drug CS060380 or a placebo (an inactive pill that looks like the study drug). Both groups will also receive semaglutide, which is an approved medicine for weight management. Neither you nor your doctor will know which treatment you are receiving.
  • A 16-week open-label period, where all participants will receive CS060380. The main goal of this study is to see how the study drug affects the amount of fat in the liver, measured by a special MRI scan, and body weight. We will also monitor your overall health and safety throughout the study by checking your vital signs, doing blood and urine tests, and asking about any side effects you might experience.

About 120 participants will take part in this study at almost 15 different hospitals across China, with Ruijin Hospital in Shanghai as the main study site.

Read the detailed description

The total study duration will not exceed 54 weeks, consisting of: screening period (up to 2 weeks), 36-week double-blind treatment period, and 16-week open-label period.

  1. The double-blind treatment period will employ a randomized, double-blind, placebo-controlled, parallel-group design.
  2. During the open-label period, all participants will receive CS060380.
  3. This study will enroll participants with MASH and obesity. About 120 participants are planned for enrollment.
  4. Eligible participants will be randomized in a 1:1 ratio to Control Group A (60 participants) and Experimental Group B (60 participants).
  5. Both groups will receive semaglutide 1.7 mg as background therapy. Control Group A will receive placebo, while Experimental Group B will receive CS060380 1.0 mg.
  6. Interim analyses will be conducted when approximately 80% of participants complete Week 16 and Week 24 visits.
  7. The sponsor will decide whether to continue the open-label study based on safety and efficacy data.
03

Conditions studied

  • Metabolic Dysfunction-associated Steatohepatitis (MASH)
  • Obesity

Browse trials for

Keywords

  • Metabolic Dysfunction-Associated Steatohepatitis
  • MASH
  • Obesity
  • CS060380
  • THR-beta agonist
  • Semaglutide
  • Phase 2 Clinical Trial
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 65 years (inclusive), male or female.
  • Liver fat content ≥10% as measured by MRI-PDFF at screening.
  • ≥30 kg/m².
  • Body weight change ≤5% during the 3 months prior to screening with only diet and exercise control (self-reported). The weight change is calculated as: (Maximum weight - Minimum weight within 3 months before screening) / Maximum weight × 100%.
  • (HbA1c) \<6.5% at screening.
  • Fasting venous blood glucose \<7 mmol/L at screening.
  • All participants with reproductive capacity agreed to take effective measures for themselves and their partners from the screening period until the end of the trial (physical contraception was used before and during the trial, and only drug contraception was used when necessary after or during the trial), and there were no recent plans for sperm donation, egg donation, or childbearing.
  • Voluntary consent to participate in this clinical trial and provide written .

Exclusion criteria

Exclusion Criteria:

Diagnosis of type 2 diabetes mellitus, type 1 diabetes mellitus, monogenic diabetes, diabetes due to pancreatic injury (e.g., post-pancreatitis diabetes), or other secondary diabetes prior to randomization.

  • ≥2 episodes of hypoglycemia (blood glucose ≤2.8 mmol/L in non-diabetic patients) within 6 months before screening.
  • Impaired gastrointestinal function or gastrointestinal disease that may affect the absorption of oral medications, such as severe gastrointestinal diseases (peptic ulcer, erosive or atrophic gastritis), partial gastrectomy, or grade >1 gastrointestinal symptoms (e.g., nausea, vomiting, or diarrhea) at screening.
  • Thyroid diseases including hyperthyroidism and hypothyroidism [participants with benign thyroid lesions (e.g., thyroid nodules) may participate in this study] or pituitary diseases, or long-term use of thyroid hormone replacement therapy, antithyroid drugs, or drugs that may affect thyroid hormone production and/or interfere with thyroid function (including but not limited to methimazole, propylthiouracil, tyrosine kinase inhibitors, lithium, iodides, and , etc.).
  • Previous diagnosis of obesity caused by endocrine diseases or single-gene mutations, including but not limited to hypothalamic obesity, pituitary obesity, hypothyroid obesity, Cushing's syndrome, insulinoma, acromegaly, and hypogonadism.
  • Previous bariatric surgery (including sleeve gastrectomy, Roux-en-Y gastric bypass, or combined procedures, etc.) or use of medical devices for obesity treatment, or planned such procedures during the trial; except for liposuction or abdominal lipectomy performed more than 1 year before screening; adjustable gastric banding with band removal more than 1 year before screening; intragastric balloon removal more than 1 year before screening.
  • Any to MRI scanning (including but not limited to severe claustrophobia, coronary artery stents, coronary implant devices, waist circumference exceeding scanner capacity making MRI-PDFF examination impossible). If coronary stents or other devices do not interfere with the function of the MRI machine, the investigator may decide at their discretion whether to allow inclusion.
  • Blood donation within 3 months before screening, or total blood loss (excluding female physiological bleeding) due to blood donation or other reasons reaching or exceeding 400 mL within 6 months.
  • Use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) or compound preparations containing GLP-1 RA components within 3 months before randomization.
  • Use of any approved or unapproved weight-loss drugs (e.g., orlistat, lorcaserin, phentermine/topiramate, naltrexone/bupropion, etc.) or drugs affecting body weight (including Chinese herbal medicines), health products, meal replacements, or weight-loss acupuncture treatments within 3 months before randomization.
  • Use of drugs that may cause significant weight gain: systemic glucocorticoid therapy for more than 1 week; tricyclic antidepressants; antipsychotic or antiepileptic drugs (e.g., imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine hydrochloride, clozapine, olanzapine, valproic acid and its derivatives, lithium preparations, thioridazine), etc., within 3 months before randomization.
  • History of treatment for more than 1 week such as total parenteral nutrition (TPN), amiodarone, methotrexate, tetracycline, tamoxifen, estrogens in excess of hormone replacement doses, anabolic steroids, valproic acid, anticholinergic drugs, or other known hepatotoxic drugs within 3 months before randomization.
  • Use of vitamin E (≥800-1000 IU/day), polyunsaturated fatty acids, ursodeoxycholic acid, fibrates, statins within 3 months before randomization, unless the participant had a stable dose for 3 months before screening, continued taking until the screening visit, and will continue the same medication regimen throughout the study participation period.
  • Use of metformin, SGLT2 inhibitors, and other hypoglycemic agents within 3 months before randomization.
  • Use of strong inhibitors of enzymes, strong inducers of CYP3A enzymes, or inhibitors of P-gp or BCRP transporters that may affect the metabolism or absorption of the study drug within 14 days before randomization or at least 5 half-lives (whichever is longer), see Appendix 1.
  • Use of hepatoprotective drugs not permitted by the protocol within 4 weeks before randomization or planned use during the clinical study, including silymarin, bicyclol, glycyrrhizin preparations (magnesium isoglycyrrhizinate, compound glycyrrhizin, diammonium glycyrrhizinate), except for ursodeoxycholic acid, polyene phosphatidylcholine, and reduced glutathione that have been stably used for ≥3 months before randomization.
  • Anticoagulant therapy within 2 weeks before randomization: drugs that increase (e.g., FXa inhibitors, warfarin, heparin, etc.).
  • History of heavy alcohol consumption for more than 3 consecutive months within 1 year before screening. Note: Heavy alcohol consumption is defined as an average weekly alcohol intake of more than approximately 7 standard drinks for women and more than approximately 14 standard drinks for men. One standard drink is defined as any beverage containing 14g of pure alcohol, such as 12 oz/360 ml of beer (5% alcohol), 8 oz/240 ml of malt liquor (7% alcohol), 5 oz/150 ml of wine (12% alcohol), 1.5 oz/45 ml of spirits (40% alcohol).
  • ≤90 g/L at screening.
  • ≥2.5× at screening.
  • AST ≥2.5×ULN at screening.
  • Serum albumin (ALB) \<35 g/L at screening.
  • International normalized ratio (INR) >1.2 at screening.
  • Total (TBil) >1.2×ULN at screening (except for Gilbert's syndrome).
  • Serum amylase or lipase ≥3×ULN at screening.
  • Calcitonin ≥50 ng/L at screening.
  • Estimated (eGFR) \<50 mL/min/1.73m² at screening.
  • abnormalities on 12-lead that, in the investigator's judgment, may affect participant safety or the interpretation of study results, such as: at screening, interval corrected by Fridericia >450 ms (males) or >470 ms (females) [Fridericia formula: QTcF = QT/(RR\^0.33)].
  • Uncontrolled hypertension: sitting systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg.
  • Previous history of acute or chronic pancreatitis, or acute or chronic pancreatitis at screening.
  • History of liver cirrhosis (e.g., the participant has undergone liver histopathological examination showing cirrhosis, or endoscopic examination suggesting esophageal and gastric varices).
  • Including other liver diseases or liver disease history, such as: PBC, PSC, alcoholic liver disease, definite liver disease or coexisting hepatitis, drug-induced liver injury, suspected or confirmed Gilbert syndrome or Wilson disease; homozygous α-1-antitrypsin deficiency; all primary iron overload diseases (including but not limited to hereditary hemochromatosis, non-hemochromatosis primary iron overload such as ceruloplasminemia, congenital transferrin deficiency syndrome, etc.) or some secondary iron overload diseases (including but not limited to transfusion-dependent iron overload, ineffective hematopoiesis-related iron overload such as MDS and sideroblastic anemia, copper-induced Parkinsonism secondary iron overload, long-term excessive iron metabolism intake, etc.), but MASH metabolism-related iron overload is excluded; drug-induced liver disease; known biliary obstruction; suspected or confirmed liver cancer or any other form of liver disease except alcoholic liver steatosis and MASH (except for those related to alcohol), known biliary obstruction, suspected or confirmed liver cancer.
  • Patients with multiple endocrine neoplasia type 2 or medullary thyroid carcinoma, or a family history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.
  • History of the following cardiovascular and cerebrovascular diseases within 6 months before screening: decompensated cardiac insufficiency ( class III or IV), arrhythmia requiring treatment, unstable angina or myocardial infarction, coronary artery bypass grafting or percutaneous coronary intervention, stroke (ischemic or hemorrhagic) or .
  • History of malignant tumor within 5 years (excluding clinically cured cervical epithelial carcinoma, squamous cell carcinoma, or basal cell carcinoma of the skin).
  • History of major depression or anxiety disorder within 2 years before screening, or current diagnosis of other mental illnesses (e.g., schizophrenia, bipolar disorder) that, in the investigator's assessment, are not suitable for participation in this trial.
  • PHQ-9 questionnaire (Depression Screening Scale) score ≥15 at screening.
  • Previous suicide attempt or suicidal behavior.
  • Known to any ingredient in semaglutide injection or to other GLP-1 RA drugs or drugs with GLP-1 receptor agonist mechanism.
  • History of (HIV) infection at screening; history of Treponema pallidum (TP) infection (except those with stable conditions judged by the investigator as suitable for inclusion in this trial); positive for surface antigen (HBsAg) [except those with HBV-DNA results below the lower limit of detection], positive for virus antibody.
  • Unwilling to cooperate, or unable to cooperate, or incapable of completing the clinical trial.
  • Suspected or confirmed history of drug or substance abuse.
  • Pregnant or lactating women; female participants of or those with menopause less than 12 months must have a negative pregnancy test during the screening period.
  • Participation in other drug clinical trials within the last 3 months.
  • In the investigator's judgment, the participant is not suitable to participate in this clinical trial.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
130 participants (actual)

Study arms

  • Placebo comparator
    Placebo + Semaglutide

    Participants receive CS060380 placebo tablets orally once daily in combination with semaglutide 1.7 mg subcutaneously once weekly for 36 weeks during the double-blind treatment period.

    Drug: semaglutide · Drug: Placebo

  • Experimental
    CS060380 1.0 mg + Semaglutide

    Participants receive CS060380 1.0 mg tablets orally once daily in combination with semaglutide 1.7 mg subcutaneously once weekly for 36 weeks during the double-blind treatment period.

    Drug: semaglutide · Drug: CS060380

Interventions

  • Semaglutide 1.7 mg as the background therapy for all participants

  • CS060380 1.0 mg tablets for the treatment of metabolic dysfunction-associated steatohepatitis complicated with obesity

  • DrugPlacebo

    Placebo tablets matching CS060380 of double-blind control for 36 weeks

06

What researchers measure

Primary outcomes

  1. Percentage change in liver fat content from baseline to Week 36 (MRI-PDFF)

    Percentage change in liver fat content measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) from baseline to Week 36 of the double-blind treatment period.

    Time frame: Baseline, Week 36

Secondary outcomes

  1. Percentage change in body weight measured by weight scale from baseline to Week 36

    Percentage change in body weight from baseline to Week 36, measured using a weight scale

    Time frame: Baseline, Week 36

  2. Percentage change in liver fat content (MRI-PDFF) from baseline to week 24

    Percentage change in liver fat content as measured by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) from baseline to Week 24

    Time frame: Baseline, Weeks 24

07

Study locations

12 sites
08

References and documents

Publications

  • Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, Sanyal AJ, Sejling AS, Harrison SA; NN9931-4296 Investigators. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. N Engl J Med. 2021 Mar 25;384(12):1113-1124. doi: 10.1056/NEJMoa2028395. Epub 2020 Nov 13. PubMed 33185364 ↗
  • Chinese Nutrition Society Obesity Prevention and Control Branch, et al. Expert consensus on obesity prevention and control among Chinese residents [J]. J Xi'an Jiaotong Univ Med Sci. 2022;43(4):619-631.
  • Fan JG, et al. Guidelines for the prevention and treatment of metabolic-associated fatty liver disease (2024 edition). J Pract Hepatol. 2024;27(4):494-510.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.

Of 131 non-industry phase 2 interventional studies under Obesity, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 57. This study's planned 12 months is below that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Mar 12, 2026
StartActual
Apr 2, 2026
Primary completionEst.
Apr 30, 2027
CompletionEst.
Jul 30, 2027
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07466017
Lead sponsor
Cascade Pharmaceuticals, Inc
Responsible party
Sponsor
First posted
Mar 12, 2026
Start date
Apr 2, 2026
Primary completion
Apr 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Aug 10, 2026

Study contacts

Weiqing Wang, Ph.D.
principal investigator · Ruijin Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CS060380

Start the discussion